Lantheus Holdings, Inc. (NASDAQ:LNTH) Position Lessened by HighTower Advisors LLC

HighTower Advisors LLC lowered its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 57.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,309 shares of the medical equipment provider's stock after selling 3,176 shares during the quarter. HighTower Advisors LLC's holdings in Lantheus were worth $207,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the company. State of New Jersey Common Pension Fund D lifted its holdings in Lantheus by 0.4% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock worth $2,364,000 after purchasing an additional 115 shares during the period. Bleakley Financial Group LLC lifted its stake in shares of Lantheus by 6.1% in the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock worth $200,000 after acquiring an additional 129 shares during the period. UMB Bank n.a. lifted its stake in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after acquiring an additional 134 shares during the period. Arizona State Retirement System boosted its holdings in shares of Lantheus by 0.9% in the fourth quarter. Arizona State Retirement System now owns 20,137 shares of the medical equipment provider's stock valued at $1,801,000 after acquiring an additional 178 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Lantheus during the third quarter valued at approximately $25,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on LNTH shares. Truist Financial increased their price target on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. B. Riley lowered their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. JMP Securities reissued a "market outperform" rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. Finally, The Goldman Sachs Group began coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price objective on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $129.43.

Lantheus Stock Performance

LNTH traded down $2.04 during trading on Tuesday, reaching $93.41. The company had a trading volume of 1,163,151 shares, compared to its average volume of 951,564. The firm's 50-day simple moving average is $93.32 and its 200 day simple moving average is $95.80. The company has a market cap of $6.40 billion, a price-to-earnings ratio of 15.54 and a beta of 0.20. Lantheus Holdings, Inc. has a 12-month low of $58.46 and a 12-month high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to analysts' expectations of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. On average, sell-side analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Buying and Selling at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the company's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now directly owns 33,207 shares of the company's stock, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 64,109 shares of company stock valued at $6,110,806 in the last three months. 1.50% of the stock is currently owned by company insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.